Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825.

Saved in:
Bibliographic Details
Title: Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825.
Authors: Scheurer ME; Baylor College of Medicine, Departments of Pediatrics and Medicine, Houston, Texas, USA., Zhou R; Baylor College of Medicine, Departments of Pediatrics and Medicine, Houston, Texas, USA., Gilbert MR; National Institutes of Health Clinical Center, Bethesda, MD, USA., Bondy ML; Baylor College of Medicine, Departments of Pediatrics and Medicine, Houston, Texas, USA., Sulman EP; M D Anderson Cancer Center, Brain and Spine Center, Houston, TX, USA.; Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, NY, USA., Yuan Y; M D Anderson Cancer Center, Brain and Spine Center, Houston, TX, USA., Liu Y; Baylor College of Medicine, Departments of Pediatrics and Medicine, Houston, Texas, USA., Vera E; National Institutes of Health Clinical Center, Bethesda, MD, USA.; M D Anderson Cancer Center, Brain and Spine Center, Houston, TX, USA., Wendland MM; National Cancer Institute, Bethesda, MD, USA.; Texas Oncology Cancer Center Sugar Land, Sugar Land, TX, USA., Youssef EF; Arizona Oncology Services Foundation, Tucson, AZ, USA., Stieber VW; Forsyth Regional Cancer Center, Winston-Salem, NC, USA., Komaki RR; M D Anderson Cancer Center, Brain and Spine Center, Houston, TX, USA., Flickinger JC; UPMC-Shadyside Hospital, Pittsburgh, PA, USA., Kenyon LC; Thomas Jefferson University Hospital, Philadelphia, PA, USA., Robins HI; University of Wisconsin Hospital, Madison, WI, USA., Hunter GK; Intermountain Medical Center, Murray, UT, USA., Crocker IR; Emory University, Winship Cancer Institute, Atlanta, GA, USA., Chao ST; Cleveland Clinic Foundation, Cleveland, OH, USA., Pugh SL; NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA., Armstrong TS; National Institutes of Health Clinical Center, Bethesda, MD, USA.
Source: Neuro-oncology advances [Neurooncol Adv] 2022 Oct 22; Vol. 4 (1), pp. vdac152. Date of Electronic Publication: 2022 Oct 22 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2632-2498
DOI:10.1093/noajnl/vdac152